Company intelligence / Profile preview

Kaixing Life Technology (Shanghai) Co., Ltd.

Shanghai, Shanghai Municipality, Chinaen.kx-alloy.com ↗

Ownership: Private
Development stage: Commercial

Overview

Kaixing Life Technology has achieved regulatory approval in China for its autologous CAR-T therapy targeting BCMA in multiple myeloma as of February 2024. The company also has a Claudin18.2-targeting monoclonal antibody program in early clinical development for advanced solid tumors, plus additional discovery-stage assets.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodiesAutologous CAR-T therapies
Industry: Biotech

Drug pipeline

1 asset

zervor-cel

Commercial

Indications: Multiple myeloma

Partnerships

Carsgen Pharmaceuticals Co., Ltd.

Beyond the preview

Go deeper on Kaixing Life Technology (Shanghai) Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaixing Life Technology (Shanghai) Co., Ltd..

Explore the full profile